5Reissig A, Mempel C, Schumacher U, et al. Microbiological diagnosis and antibiotic therapy in patients with community- acquired pneumonia and acute COPD exacerbation in daily clinical practice : comparison to current guidelines[J] Lung,2013,191(3):239-246.DOI:10.1007/s00408-013-9460-x.
6Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy . Chest, 2007, 131 (1) :9-19. DOI: 10. 1378/chest. 06-1500.
7Sehuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial [J] JAMA, 2009, 302 (10) : 1059-1066. DOI: 10. 1001/jama. 2009. 1297.
9Juli6n-Jimnez A, Timbn Zapata J, Laserna Mendieta EJ, et al. Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department [J]. Enferm In{ecc Microhiol Clin, 2014,32(4) : 225-235. DOI: 10. 1016/j. eime. 2013.04. 015.
10American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare- associated pneumonia[J]. Am J Respir Crit Care Med, 2005, 171 (4) : 388-416. DOI : 10.1164/rccm. 200405-644ST.
